(Q57261195)

1

0 references

author name string

Lucy Feng

2

0 references

Jennifer E. Morgan

3

0 references

Francesco Muntoni

Dystrophin: the protein product of the Duchenne muscular dystrophy locus

4

0 references

language of work or name

English

0 references

publication date

10 July 2012

0 references

published in

Nature Reviews Neurology

0 references

volume

8

0 references

issue

8

0 references

page(s)

469-469

0 references

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.15-C1

Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.15-C1

Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.15-C1

Dystrophin immunity in Duchenne's muscular dystrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.15-C1

Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.15-C1

Immunohistological intensity measurements as a tool to assess sarcolemma-associated protein expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.15-C1

Revertant fibres and dystrophin traces in Duchenne muscular dystrophy: Implication for clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.15-C1

Restoration of the dystrophin-associated glycoprotein complex after exon skipping therapy in Duchenne muscular dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.15-C1

Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.15-C1

Chronic systemic therapy with low-dose morpholino oligomers ameliorates the pathology and normalizes locomotor behavior in mdx mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.15-C1

Long-term systemic administration of unconjugated morpholino oligomers for therapeutic expression of dystrophin by exon skipping in skeletal muscle: implications for cardiac muscle integrity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.15-C1

Quantification of dystrophin immunofluorescence in dystrophinopathy muscle specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.15-C1

185th ENMC International Workshop: stem/precursor cells as a therapeutic strategy for muscular dystrophies 3-5 June 2011, Naarden, The Netherlands

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.15-C1

Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22777248

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Neuromuscular disease. A novel imaging method to quantify low levels of dystrophin in Duchenne muscular dystrophy

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22777248